Intrawound Vancomycin To Prevent Periprosthetic Joint Infection in Total Knee Arthroplasty .
Efficacy of Intrawound Vancomycin in Prevention of Periprosthetic Joint Infection After Primary Total Knee Arthroplasty: A Prospective Double-Blinded Randomized Control Trial.
J Arthroplasty . 2024 Jun;39(6):1569-1576.1,022 patients with primary knee osteoarthritis were randomized to receive either 2 grams of intrawound vancomycin powder (n=507) or no vancomycin (control, n=515) before arthrotomy closure. The primary outcome of interest was the incidence of periprosthetic joint infection (PJI) or surgical site infection (SSI). Secondary outcomes included rates of minor wound complications, reoperation rates, and nephrotoxicity incidence. Outcomes were assessed up to 12 months postoperatively. Overall, the study found no significant difference in PJI/SSI rates between the two groups. However, the vancomycin group showed a significantly higher incidence of minor wound complications.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
